AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical trial titled ‘A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)’. The study aims to evaluate the efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig alone compared to pembrolizumab monotherapy in treating advanced non-squamous NSCLC.
Intervention/Treatment: The study tests three interventions: Datopotamab Deruxtecan (Dato-DXd) combined with Rilvegostomig, Rilvegostomig monotherapy, and Pembrolizumab monotherapy. These treatments are administered as intravenous infusions every three weeks, targeting high PD-L1 expression in NSCLC patients.
Study Design: This interventional study employs a randomized, parallel assignment model with single masking. The primary purpose is treatment, focusing on comparing the new combination therapies against the standard pembrolizumab monotherapy.
Study Timeline: The study began on April 11, 2024, with its primary completion and estimated overall completion dates yet to be announced. The last update was submitted on June 27, 2025, indicating ongoing recruitment and progress.
Market Implications: The progress of this study could significantly impact AstraZeneca’s stock performance, particularly if the combination therapies demonstrate superior efficacy. Success in this trial could enhance AstraZeneca’s competitive edge in the oncology market, potentially influencing investor sentiment positively. Competitors in the NSCLC treatment space will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.